TY - JOUR
T1 - Induced pluripotent stem cell lines derived from human somatic cells
AU - Yu, Junying
AU - Vodyanik, Maxim A.
AU - Smuga-Otto, Kim
AU - Antosiewicz-Bourget, Jessica
AU - Frane, Jennifer L.
AU - Tian, Shulan
AU - Nie, Jeff
AU - Jonsdottir, Gudrun A.
AU - Ruotti, Victor
AU - Stewart, Ron
AU - Slukvin, Igor I.
AU - Thomson, James A.
PY - 2007/12/21
Y1 - 2007/12/21
N2 - Somatic cell nuclear transfer allows trans-acting factors present in the mammalian oocyte to reprogram somatic cell nuclei to an undifferentiated state. We show that four factors (OCT4, SOX2, NANOG, and LIN28) are sufficient to reprogram human somatic cells to pluripotent stem cells that exhibit the essential characteristics of embryonic stem (ES) cells. These induced pluripotent human stem cells have normal karyotypes, express telomerase activity, express cell surface markers and genes that characterize human ES cells, and maintain the developmental potential to differentiate into advanced derivatives of all three primary germ layers. Such induced pluripotent human cell lines should be useful in the production of new disease models and in drug development, as well as for applications in transplantation medicine, once technical limitations (for example, mutation through viral integration) are eliminated.
AB - Somatic cell nuclear transfer allows trans-acting factors present in the mammalian oocyte to reprogram somatic cell nuclei to an undifferentiated state. We show that four factors (OCT4, SOX2, NANOG, and LIN28) are sufficient to reprogram human somatic cells to pluripotent stem cells that exhibit the essential characteristics of embryonic stem (ES) cells. These induced pluripotent human stem cells have normal karyotypes, express telomerase activity, express cell surface markers and genes that characterize human ES cells, and maintain the developmental potential to differentiate into advanced derivatives of all three primary germ layers. Such induced pluripotent human cell lines should be useful in the production of new disease models and in drug development, as well as for applications in transplantation medicine, once technical limitations (for example, mutation through viral integration) are eliminated.
UR - http://www.scopus.com/inward/record.url?scp=36749043230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749043230&partnerID=8YFLogxK
U2 - 10.1126/science.1151526
DO - 10.1126/science.1151526
M3 - Article
C2 - 18029452
AN - SCOPUS:36749043230
SN - 0036-8075
VL - 318
SP - 1917
EP - 1920
JO - Science
JF - Science
IS - 5858
ER -